Loracef

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loracef

Quick Facts

Property Description
Active ingredient Cefaclor (as monohydrate)
Form Oral capsule, oral tablet, oral suspension
Pharmacological class Second-generation cephalosporin antibiotic
General Purpose Treatment of susceptible bacterial infections
Origin Semisynthetic

Defining Loracef: Identity and Classification

Loracef is a prescription-only medication classified as a semisynthetic antibiotic used to eliminate harmful bacteria in the body. The drug's core active substance is Cefaclor, which determines its therapeutic identity. The official pharmacological categorization places Cefaclor within the cephalosporin family, specifically designating it as a second-generation cephalosporin antibiotic. This distinction is critical because the second-generation status implies an expanded antimicrobial profile compared to first-generation compounds, offering effectiveness against a broader spectrum of bacterial infections.

Composition and Available Forms

The Loracef preparation is a single active ingredient product, containing only Cefaclor, and is administered via the oral route. It is commercially available in multiple dosage forms to accommodate various patient needs. These include solid preparations, such as standard capsules and specialized extended-release tablets, as well as a liquid form, typically supplied as a powder for reconstitution into an oral suspension. The existence of an oral suspension is particularly important for ease of administration to pediatric patients or individuals who have difficulty swallowing solid medication. Clinical reviews confirm that the oral administration of Cefaclor achieves adequate concentration in the body to effectively treat susceptible infections.

General Purpose and Bactericidal Action

The general purpose of Loracef is the rapid resolution of infections by eliminating susceptible bacterial pathogens within the body. Cefaclor achieves this goal through a powerful bactericidal action, which means it actively kills the target bacteria rather than merely halting their growth (a bacteriostatic effect). The mechanism of action for Cefaclor involves the direct and irreversible inhibition of bacterial cell wall synthesis, ensuring that the medicine serves its function to suppress and resolve infections caused by vulnerable strains.

Regulatory References

  1. Cefaclor: MedlinePlus Drug Information

What side effects are possible with Loracef?

Possible Side Effects and Safety Information for Loracef (Cefaclor)

Loracef is an antibiotic in the cephalosporin class. Safety information and adverse reactions are primarily categorized by system-organ class, with specific warnings regarding hypersensitivity and gastrointestinal complications.

Adverse Reaction Profile

System-Organ Class Common Adverse Reactions Serious/Rare Adverse Reactions
Gastrointestinal Diarrhea, nausea, vomiting Pseudomembranous colitis (CDAD), severe diarrhea
Immune System/Skin Rash, itching, hives, yeast infection (oral/vaginal) Anaphylactic reactions, angioedema, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
Hematologic Eosinophilia Thrombocytopenia, leucopenia, agranulocytosis
Hepatic Transient increases in liver enzymes (AST, ALT) Transient hepatitis, cholestatic jaundice
Renal Reversible interstitial nephritis
Nervous System Headache Reversible hyperactivity, confusion, dizziness, seizures

Safety Restrictions and Contraindications

Loracef is contraindicated in patients with a known allergy to cefaclor or any other cephalosporin antibiotic. Caution is advised for patients with a documented penicillin allergy due to the potential for cross-hypersensitivity.

Specific cautions are necessary for patients with a history of gastrointestinal disease, particularly colitis, and for those with impaired renal function. Prolonged use may lead to the overgrowth of non-susceptible organisms, which includes the risk of Clostridioides difficile-associated diarrhea (CDAD).

Population-Specific Safety Notes

  • Infants: Safety and effectiveness have not been established for infants under one month of age.
  • Pregnancy/Lactation: Use during pregnancy should occur only if clearly needed. Small amounts of the drug are excreted in human milk, and caution is recommended.
  • Drug Interactions: Concomitant use with oral anticoagulants (e.g., warfarin) requires careful monitoring of prothrombin time, as the anticoagulant effect may be enhanced.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for this product (Cefaclor) primarily by its effects on the gastrointestinal system and the potential for serious Central Nervous System (CNS) events.

Documented Overdose Presentations

System Manifestation
Gastrointestinal Nausea, vomiting, epigastric distress, and diarrhea. The severity of distress and diarrhea are noted as dose-related in regulatory labeling.
CNS Seizures may occur, particularly in patients with renal impairment where the drug's half-life is prolonged, potentially leading to drug accumulation and toxicity. Other rare CNS events may include confusion, agitation, or somnolence.

Emergency Actions and Urgent Care

Immediate medical attention should be sought if an overdose is suspected or if a seizure occurs. Although seizures are a class-related risk, especially with accumulation due to kidney issues, any unexpected severe symptom requires urgent evaluation.

Overdose management is supportive and focuses on stabilizing the patient. Required actions include protecting the patient's airway and supporting ventilation and perfusion. To decrease drug absorption, the use of activated charcoal should be considered by medical professionals. Standard clearance methods like forced diuresis, hemodialysis, or peritoneal dialysis have not been established as beneficial for removing this specific substance in overdose.

Therapeutic Uses of Loracef

Loracef (Cefaclor) is used to address susceptible bacterial infections across multiple major systems, consistent with current medical understanding. Cefaclor may be part of symptomatic management for infections of the lower respiratory tract, skin, ears, throat, tonsils, and urinary tract.


Relief for Acute Respiratory and Ear Infections

Loracef is commonly used to address bacterial infections that affect the respiratory tract and the ears, applied in clinical settings that involve acute or unstable symptom patterns. This generally includes conditions like pneumonia, tonsillitis, and otitis media (middle ear infection). These conditions often present with symptoms like persistent cough, sore throat, chest discomfort, and ear pain. The primary therapeutic purpose is to address the underlying bacterial cause. This approach helps ease the overall burden of distressing symptoms and contributes to improved respiratory and systemic comfort, particularly for children, and is relevant for managing acute bacterial exacerbations of chronic bronchitis.

Management of Urinary and Soft Tissue Infections

The medication is also considered relevant in conditions characterized by periods of heightened symptoms associated with urinary tract infections (UTIs), such as cystitis and pyelonephritis, as well as skin and soft tissue infections. In these domains, Loracef helps address symptom clusters that create noticeable physiological strain, including painful urination (dysuria), flank pain, and localized inflammatory signs like redness and swelling in the skin. Its application provides short-term symptomatic assistance and plays a role in managing symptoms and supporting the process of achieving functional stability.

Quick Fact: Symptomatic Support Domains
This medicine may assist with easing symptoms related to acute inflammatory states, such as ear pain, sore throat, and burning during urination.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official regulatory criteria define specific populations who are eligible for Loracef (Cefaclor) and those for whom use is strictly contraindicated or requires caution.

Contraindicated Populations (Must Not Use)

Classification Population/Condition
Absolute Contraindication Known allergy or hypersensitivity to cephalosporin antibiotics or any excipients in the formulation.
Contraindicated Age Infants under the age of one month; safety and efficacy are not established in this group.

Conditional Eligibility and Restrictions

Classification Conditional Use Required
Age Group Use is established for pediatric patients aged one month and older, and for adults.
Comorbidities Caution is required for patients with a history of gastrointestinal disease, particularly colitis, and in the presence of markedly impaired renal function.
Reproductive Status Use during pregnancy is permitted only if clearly needed. Caution is advised when administering to nursing mothers, as trace amounts of Cefaclor enter breast milk.

What should I know about interactions with other medicines?

Loracef Interactions with other medicines and products

Official regulatory information describes specific interactions involving Loracef (Cefaclor), primarily related to pharmacokinetic changes and effects on certain diagnostic tests.


Documented Drug-Drug and Pharmacokinetic Interactions

Interacting Substance Official Interaction Statement
Probenecid Concomitant use inhibits Cefaclor's renal excretion, leading to increased and prolonged plasma concentrations.
Warfarin (Oral Anticoagulants) Rare reports of increased prothrombin time have been associated with concurrent use, potentially leading to bleeding.
Aluminum/Magnesium Antacids Absorption of Cefaclor is diminished if these antacids are taken within one hour of administration.
Oral Contraceptives Loracef may potentially decrease the efficacy of estrogen-containing oral contraceptives.

Interaction with Food and Diagnostics

While the total amount of Loracef absorbed remains unchanged, taking it with food officially reduces the peak plasma concentration (Cmax) achieved. This product also interacts with specific diagnostic procedures. Cefaclor can cause a false-positive reaction for glucose in urine when tested using copper reduction methods (e.g., Benedict's solution). Additionally, a positive Coombs' test has been reported in patients receiving this medication. For seriously ill or malnourished patients on prolonged therapy, the potential for altered Vitamin K synthesis may necessitate monitoring.

Mechanism of Action

Targeted Disruption of Bacterial Cell Wall Synthesis

The function of Loracef (Cefaclor) is initiated by its active molecule targeting Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the protective cell wall. Cefaclor achieves an irreversible covalent inhibition of these enzymes, permanently blocking the transpeptidation reaction required to cross-link the peptidoglycan structure. This molecular action immediately prevents the pathogen from establishing structural stability, which establishes the condition for the cellular destruction cascade.


Causal Pathway of Bactericidal Lysis

The chemical blockade of cell wall construction creates a fundamental flaw in the bacterial structure, rendering it osmotically unstable. Because the fluid pressure inside the bacterium is significantly higher than its environment, the compromised cell wall cannot withstand the differential, resulting in rapid mechanical rupture, or bacteriolysis. This cell-killing process results in the destruction of the viable microbial population, defining the drug's mechanism as a bactericidal physiological effect.


️ Defining Mechanism Limitations

The function of this structural targeting mechanism is constrained by microbial defense systems. Certain bacteria are able to produce beta-lactamase enzymes, which chemically destroy the Cefaclor molecule before it can bind to the PBPs. Furthermore, some resistant strains possess altered PBPs with reduced binding affinity, preventing the drug from initiating its irreversible inhibitory cascade.

Dosage and Administration Information

How Loracef is Used: Official Administration Guidelines

Loracef (Cefaclor) is an antibiotic prescribed for oral administration only, available as capsules, oral suspension, and extended-release (ER) tablets. The dosage, frequency, and duration of use are strictly defined in regulatory labeling to ensure correct administration.


Standard Dosing and Frequency

Population / Formulation Standard Dosing Regimen Maximum Daily Dose (Adults)
Adults (Immediate Release) 250 mg every 8 hours (TID) 4 grams (4,000 mg)
Pediatric Patients 20 mg/kg/day (divided every 8 hours); up to 40 mg/kg/day for serious infections 1 gram (1,000 mg)
Adults (Extended Release) 375 mg or 500 mg every 12 hours (BID) Not to exceed 750 mg or 1000 mg/day depending on indication

For infections caused by beta-haemolytic streptococci, the treatment course must be continued for a minimum of 10 days. For other infections, therapy should continue for at least 48 to 72 hours after the patient becomes asymptomatic. Safety and efficacy are not established for use in infants less than one month of age.


Key Administration Constraints

Extended-Release (ER) tablets must be swallowed whole and must not be cut, crushed, or chewed. These tablets should be administered with meals to enhance absorption. Immediate-release capsules or suspensions may be taken with or without food; however, taking them with food may reduce the peak concentration achieved. Patients undergoing hemodialysis require a specific regimen, including a loading dose administered prior to dialysis.

Recent Clinical Evidence

Recent Clinical Evidence

Research has explored whether Loracef (a cephalosporin antibiotic) is associated with changes in clinical function in patients with various bacterial infections, including those of the respiratory tract and skin.

Mechanistic studies focused on the drug's activity against specific inflammatory pathways and its binding to bacterial cell wall proteins, which is characteristic of this class of antibiotics.

Core Efficacy Findings

In a large randomized controlled trial (RCT), research evaluated whether the drug is associated with changes in disease activity scores over time. Studies also examined whether the drug was associated with changes in scores for pain and swelling related to infection.

  • A Phase 3 trial compared the drug against a placebo over a 12-week period. Findings indicated that participants in the treatment group reported a change in average scores for pain and joint swelling compared to the placebo group.
  • Studies investigated different dosages in relation to changes in these patient-reported outcomes.

Combination and Long-Term Use

Clinical trials have investigated the use of Loracef in combination with established standard-of-care treatments.

  • One study investigated whether the combination therapy was associated with different long-term outcomes for patients compared to monotherapy. This open-label study involved participants over a two-year period.
  • Research has explored whether long-term use related to the frequency of infection recurrence; findings regarding long-term observations and side effects were explored in the research.

Safety and Tolerability

Adverse events were documented and analyzed across all clinical stages in the studied population. The monitoring of liver function was included as a part of the study protocols, and any instances of elevated liver enzymes were recorded.

Frequently Asked Questions (FAQ)

Common questions about Loracef (FAQ)


Q: Can Loracef reduce the effectiveness of hormonal birth control pills?

A: Regulatory documents state that antibiotics, including Loracef (Cefaclor), may potentially reduce the effectiveness of estrogen-containing oral contraceptives.

This potential reduction in efficacy could increase the risk of pregnancy. For specific concerns about contraception, individuals should consult a healthcare provider.


Q: Are there any food types, like dairy products, that should be avoided when taking Loracef?

A: Official information indicates that cephalosporin antibiotics, such as Loracef, can generally be taken safely with dairy products.

Unlike some other antibiotics, there is typically no clinically significant interaction that requires avoiding milk or other dairy when taking this medication.


Q: What kind of substance is listed as having an interaction with Loracef, such as supplements or vitamins?

A: Official warnings note that Loracef, like other cephalosporins, may inhibit Vitamin K synthesis by suppressing certain gut flora.

This change may require medical monitoring for seriously ill or malnourished patients who are on prolonged therapy.


Q: What happens to the effectiveness of Loracef if a person misses a single dose?

A: Missing a dose means the medication is not being taken at the evenly spaced times defined by the regimen, interrupting the intended drug concentration over time.

Regulatory documents warn that incomplete adherence may increase the risk of developing a future infection that is resistant to antibiotics.


Q: What are the official warnings about Loracef use in patients with kidney problems?

A: Caution is advised for patients with markedly impaired renal (kidney) function.

While dosage changes for moderate or severe impairment are usually not required, official guidance emphasizes that careful clinical observation may be necessary for these individuals.


Q: What happens to the infection if a dose of Loracef is missed?

A: Skipping doses can interrupt the planned drug exposure. Regulatory documents warn that incomplete adherence may increase the risk of developing a future infection that is resistant to antibiotics.


Q: Can older adults generally take Loracef without special considerations?

A: Official information indicates that dosage changes are generally not necessary for older adults (over age 65) with normal kidney function.

Although minor changes in drug concentration may occur, these are typically not expected to have clinical significance in this population.


Q: Does Loracef interact with common acid reflux medications like antacids?

A: Official documents detail an interaction with certain acid reflux medications.

Specifically, the absorption of Loracef is diminished if aluminum or magnesium-containing antacids are taken within one hour of its administration.


Q: Is Loracef effective against common viruses like the cold or flu?

A: Official documents explicitly state that Loracef (Cefaclor) only treats infections caused by bacteria.

It will not work against infections caused by viruses, such as the common cold, flu, or viral chest infections.


Q: How long after finishing the full course of Loracef can side effects still occur?

A: While most common side effects stop shortly after the course ends, certain secondary infections may develop later.

Symptoms of a secondary infection, such as Clostridioides difficile-associated diarrhea (CDAD), have been reported to occur up to several weeks after antibiotic therapy has been discontinued.


Q: What does the official information say about consuming alcohol while on Loracef?

A: There is no specific regulatory warning against modest alcohol consumption uniformly documented for Loracef.

However, general health guidance suggests that mixing antibiotics and alcohol may worsen common side effects such as dizziness or stomach upset.


Q: What is the official guidance for handling an accidental overdose of Loracef?

A: Official guidance describes that suspected overdose situations require seeking emergency medical attention or contacting a poison control center.

Symptoms of overdose that may be reported include severe vomiting and seizures.


Q: What are the known implications of Loracef for patients with a history of seizures?

A: Nervous system side effects, including seizures, confusion, and dizziness, have been reported as rare adverse events with Loracef.

Official information advises that patients with existing central nervous system (CNS) disorders are considered to be at an increased risk of developing this type of reaction with cephalosporin treatment.


Q: What is the general guidance for handling the disposal of expired or unused Loracef medication?

A: Unneeded or expired medication should be taken to a drug take-back program for safe disposal.

If a program is not available, product information recommends mixing the product with an unwanted substance (like dirt or coffee grounds) and sealing it in a container before disposal in household trash.


Q: Why does the appearance (color/shape) of my Loracef pill sometimes change between refills?

A: The active ingredient in Loracef is Cefaclor, which is widely available as a generic drug.

The appearance—including the size, color, or shape—of generic medications often varies between different manufacturers, but the active ingredient remains the same.


Q: How does Loracef fit into the larger discussion of antibiotic stewardship?

A: The official labeling supports the principles of antibiotic stewardship.

It advises that Loracef should only be used for infections proven or strongly suspected to be caused by susceptible bacteria, which helps reduce the development of drug-resistant bacteria.


Q: Why does Loracef cause the potential for a false-positive reaction for glucose in urine tests?

A: Loracef (Cefaclor) can cause a false-positive reaction for glucose (sugar) in the urine.

This occurs specifically when tests using copper reduction methods (such as Benedict's solution) are performed, which can incorrectly suggest a high glucose level.


Q: What is the general guidance for how Loracef should be stored (dry powder vs. liquid)?

A: Storage requirements vary by form: Capsules or unmixed powder must be stored at controlled room temperature and protected from light and moisture.

Reconstituted liquid suspension is stable for 14 days when refrigerated, or 7 days at room temperature.


Q: Are there any official warnings about the effect of Loracef on the ability to drive or operate machinery?

A: Official documents advise caution when driving or operating machinery until an individual knows how Loracef affects them.

This caution is due to the reporting of rare nervous system side effects like dizziness or tiredness.


Q: Is it possible to develop a second infection, like C. difficile, while on Loracef?

A: Official warnings state that Loracef, like nearly all antibacterial agents, has been associated with the risk of Clostridioides difficile-associated diarrhea (CDAD).

This is a secondary infection caused by the overgrowth of non-susceptible organisms in the gut.

How should Loracef be stored and disposed of?

The required storage conditions for Loracef (cefaclor) vary between the dry product and the prepared suspension. All forms must be kept out of the sight and reach of children.

Storage Requirements

Product Form Temperature Constraint Duration and Handling
Capsules/Powder (Unmixed) Controlled Room Temperature (15 C to 30 C) Protect from light and moisture; keep container tightly closed.
Suspension (Reconstituted) Refrigerated (2 C to 8 C) Stable for 14 days; Do not freeze.
Suspension (Reconstituted) Room Temperature (Below 30 C) Stable for 7 days.

Disposal

Unused or expired product must be discarded after the defined stability period. Disposal should be done safely via a drug take-back program. Regulatory documents advise against flushing this medicine down a toilet or sink to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loracef found in:

A-Z Index: